As the executive chairman of the Board of Directors of Emergent BioSolutions Inc. in Gaithersburg, Maryland, Fuad El-Hibri is responsible for the development and manufacturing of vaccines and other treatments to fight diseases. Under the direction of Fuad El-Hibri, Emergent BioSolutions has manufactured an anthrax vaccine known as BioThrax.
Developed to help prevent anthrax, BioThrax has been tested in more than 25 studies and on over 500,000 people. Designed to be used prior to any exposure, the vaccine is approved for those between the ages of 18 and 65 who could be potential high-risk candidates. BioThrax can also be used after possible exposure to anthrax when used with recommended antibacterial drugs.
BioThrax works by stimulating the body’s immune system and helping to produce antibodies that protect against the protective antigen (PA) bacteria that carries the anthrax disease. By blocking the PA bacteria, it helps the body fight off the disease.